Abbreviations: aGvHD = acute GvHD; cGvHD = chronic GvHD; D = donor; GI = gastrointestinal; HL = Hodgkin's lymphoma; H = host; MDS = myelodysplastic syndrome; MMF = mycofenolate mofetil; NHL = non-Hodgkin's lymphoma.
A major hurdle to the field of allogeneic hematopoietic stem cell transplantation (HSCT) is the lack of validated biomarkers of protective immunity against opportunistic infections, including CMV reactivation syndromes. 1 This issue is particularly relevant to alternative-donor settings, for example, HLA-haploidentical HSCT (haplo-HSCT) and cord blood transplantation, where aggressive GvHD prophylaxis results in a profound and long-lasting state of immune incompetence. Despite the introduction of routine post-transplant viral monitoring and preemptive antiviral therapy, CMV reactivation syndromes remain a major cause of transplantrelated mortality. Accordingly, serological evidence of prior CMV infection is still one of the main negative prognostic factors in HSCT. 2 Different studies have demonstrated that a faster recovery of CMV-specific T-cell responses associates with a reduced CMV reactivation incidence in HSCT from HLA-identical sibling and matched unrelated donors. 3, 4 Given its clinical and biological peculiarities, it is currently unknown whether these observations are directly translatable to the haplo-HSCT setting. In this study, while aiming to follow the recovery of CMV-specific T-cell responses after haplo-HSCT, we unexpectedly found that protective levels of CMV immunity were associated with a reduced incidence of severe infections overall.
We retrospectively evaluated 175 consecutive patients undergoing haplo-HSCT and enrolled in two experimental protocols investigating either CD34-selection (TK007 5 ) or post-transplant sirolimus (TrRaMM 6 ) as GvHD prophylaxis. TK007 patients received suicide gene-modified donor lymphocytes infusions (10E7 T cells/kg) starting from day 30 after transplantation, whereas TrRaMM patients received an unmanipulated graft containing 10E8/kg T cells. Inclusion criteria were: CMV seropositivity (either host or donor), survival beyond day 30 and availability of T-cell counts. Ninety-two patients (Table 1) fulfilled these criteria and were evaluated for immune reconstitution, infectious serious adverse events (infectious SAEs) and CMV reactivation. The proportion of patients experiencing infectious SAEs, defined as infections by either viruses, bacteria or fungi requiring systemic therapy or hospitalization, is detailed in Figure 1a at each month until 1 year after haplo-HSCT. During the first month, the incidence of bacterial infections (26.1%) was equal to that of viral ones (26.1%), whereas fungal infections were 7.6%. From the second month on, the incidence of bacterial and fungal infections subsided, whereas viral ones became prevalent. Given the high prevalence of CMV seropositivity in Southern Europe, 7 at our center, patients received an intense CMV prophylaxis, consisting of gancyclovir (10 mg/kg/day) during conditioning, followed by foscarnet (90 mg/kg/day) from day 4 to day 20 and oral acyclovir (1600 mg/day) thereafter, until day 100. Moreover, as a measure of active surveillance, we monitored CMV reactivation by either CMV antigenemia or DNAemia twice weekly until day 100 and monthly thereafter, until 1 year. The CMV DNAemia was measured on plasma by using the ready-to-use CMV RGQ kit for real-time qPCR (QIAGEN, Germantown, MD, USA). The assay displays high sensitivity (detection limit 43 copies/mL) and allows accurate DNAemia quantitations over a broad linear range (from 79 to 10E8 copies/mL). Preemptive therapy was given in cases of CMVantigen positivity or CMV DNAemia 41000 copies/mL and consisted of ganciclovir (5 mg/kg/day) or foscarnet (90 mg/kg/ day), until the tests became negative.
The proportion of patients reactivating CMV or developing CMV disease at each month, until 1 year after HSCT is provided in Figure 1b . The switch from intravenous to oral antiviral therapy at day 20 possibly explains the increased CMV reactivation incidence during the second month. From the third month on, however, the CMV reactivation incidence gradually decreased, with o 10% of patients experiencing CMV reactivation after 6 months. Despite that, the few CMV reactivation events recorded at later time points were clinically relevant, often causing CMV-related syndromes.
In the same patients, we also evaluated the frequencies of CMV-specific T cells ex vivo at different time points post transplant. Looking for an assay that concurrently had the lowest possible detection limit, was not dependent on predefined HLA alleles and allowed the assessment of both CD4 and CD8 immunity, we gave preference to IFN-gamma Enzyme-Linked ImmunoSpot (ELISpot) after stimulation with lysates of CMV-infected fibroblasts. Using CMV-specific CD8 + CTL clones as immunological probes, we measured that infected-cell extracts allow detecting one-third of MHC-class I-restricted responses compared with cognate peptides (not shown). We however, reasoned that such a level of underestimation was well compensated by the broad repertoire of epitopes available for cross-presentation on MHC-I molecules. 8 Given the high variability of CD3 + absolute counts early after transplantation, ELISpot results were normalized for the CD3 content of the PBMC sample and expressed as spot-forming cells (sfc)/μL. Using receiver operating characteristic ROC curve analysis, we found that a cutoff value of 1 CMV sfc/μL allowed discrimination with high specificity (495%) of patients who did not reactivate the virus afterwards. At 30 days, 5/23 patients (21.7%) had a N of CMV-specific T cells 41 sfc/μL, with one developing viremia that required antiviral therapy. At 90 days, 9/31 patients (29.0%) reached this threshold, with no one developing clinically relevant viremia. Finally, at 180 days, 9/17 patients (52.9%) had a N of CMV-specific T cells 41 sfc/μL and none of them developed viremia. Overall, the true positives were 21, whereas there was only one false positive (positive predictive value, 95%). The true negatives and false negatives were 19 and 30, respectively (negative predictive value, 39%). Eighteen out of the 30 patients (60%) who did not reach the cutoff experienced infectious SAEs, mainly due to viruses (25 episodes, 65.7%), but also to other pathogens (two fungal infections, 5.3%; 6 bacterial infections, 15.8%; five unknown infections: 13.2%), compared with only 3/14 patients (21.4%) rapidly recovering CMV immunity (one viral, one bacterial and one unknown infection). After correcting for the confounding effects of disease relapse/progression by competitive-risk analysis using the R software (R-project, Vienna, Austria), 9 we found that the 1-year cumulative incidence of infectious SAEs in patients recovering protective CMV immunity was significantly lower than that of patients who did not (21% vs 57%, P o 0.05, Figure 1c ). Vice versa, disease relapse/progression rates were not significantly different between the two groups ( Figure 1d) . Strikingly, none of the three patients dying from infections, including one case of fatal CMV pneumonia, achieved the protective value of 1 CMV sfc/μL.
The quite unexpected finding that the early recovery of protective CMV immunity after haplo-HSCT associated with a reduced incidence of severe infections overall, including those from fungi and bacteria, suggests its usefulness as a biomarker of general immune competence against opportunistic and nonopportunistic pathogens. Other studies have explored ELISpot analysis as a means to follow the recovery of CMV immunity after HSCT. In a recent pediatric study, it was found that reaching a value of 80 CMV sfc per 200 000 PBMCs post transplant was associated with protection from CMV reactivation. 10 Given the high variability of CD3 + counts among the different HSCT settings and between patients, this value is hardly translatable to other series. Conversely, by normalizing CMV-specific T cells for the content of CD3 + cells in the PBMC sample, we found that our threshold of one CMV sfc/mL was remarkably similar to the one identified in another study in HLA-matched HSCT. 11 Although investigated in an admittedly heterogeneous haplo-HSCT cohort, our findings therefore confirm ELISpot as an easily translatable method for assaying protective CMV immunity regardless of the HSCT procedure. Recently, CMV reactivation after HSCT has been found to inversely correlate with leukemia-relapse incidence, 12 possibly due to the stimulation of cross-reactive leukemia specificities. Although tempting, speculation that CMV immunity might have participated to the GvL effect observed in our study was not confirmed. Besides its small size, another possible explanation for this discrepancy could be that the ELISpot assay might have missed NK-cell responses 13, 14 and/or γ/δ T-cell responses, 15 which have been both called into question to explain this phenomenon.
In summary, the results of our study suggest that the evaluation of CMV-specific T-cell responses by ELISpot might be of important added value to current monitoring policies after haplo-HSCT, not only allowing mitigation of CMV surveillance and minimization of overtreatment, but also crucially surrogating important clinical outcome measures. Final confirmation of our findings obviously awaits a larger multi-center prospective study, an endeavor that previously requires harmonization of the ELISpot assay. 
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